Identification of PAFAH1B3 as Candidate Prognosis Marker and Potential Therapeutic Target for Hepatocellular Carcinoma

Weikang Xu†, Xinyu Lu†, Jing Liu†, Qianhui Chen†, Xuan Huang†, Kuiyuan Huang†, Hongyan Liu†, Wei Zhu† and Xiaoyong Zhang†*

1 State Key Laboratory of Organ Failure Research, Guangdong Provincial Key Laboratory of Viral Hepatitis Research, Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, Guangzhou, China, 2 Department of Hematology, The Seventh Affiliated Hospital of Sun Yat-sen University, Shenzhen, China

Background: Hepatocellular carcinoma (HCC) is the fourth leading cause of cancer-related deaths worldwide. PAFAH1B3 plays an important role on occurrence and development in a variety tumor. However, the function of PAFAH1B3 in HCC remains unclear.

Methods: The TIMER, ONCOMINE, Human Protein Atlas (HPA), GEPIA, The Cancer Genome Atlas (TCGA), HCCDB, UALCAN and LinkedOmics database were used to analyze the prognostic value, co-expression genes and regulator networks of PAFAH1B3 in HCC. siRNA transfections and inhibitor of PAFAH1B3 P11 were used to verify the anti-tumor effect on HCC cell lines. Gene expression was detected by qRT-PCR. The functions of PAFAH1B3 downregulation in HCC cell lines were investigated using cell cycle analysis, apoptosis detection, CCK8 assay and transwell assay. Western blot was used to evaluate the role of PAFAH1B3 on metabolic pathways in HCC cells.

Results: Based on the data from databases, the expression of PAFAH1B3 was remarkably increased in HCC patients. High expression of PAFAH1B3 was associated with poorer overall survival (OS) and disease-free survival (DFS). And PAFAH1B3 was notably linked to age, sex, grade, stage, race, and TP53 mutational status. Then, the functional network analysis showed PAFAH1B3 may be involved in HCC through cell cycle, cell metabolism, spliceosome, and RNA transport. Furthermore, the mRNA expression of PAFAH1B3 was also increased in HCC cell lines. Flow cytometry analysis showed that PAFAH1B3 manipulated apoptosis and cell cycle regulation. CCK8 assay showed that PAFAH1B3 silencing or pharmacologic inhibitor of PAFAH1B3 inhibited the proliferation of HepG2, Huh7 and MHCC-97H cells. Transwell assay results showed that PAFAH1B3 silencing also significantly impaired the invasion and migratory ability of HCC cells. In addition, PAFAH1B3 silencing significantly downregulated the expression of glycolysis and lipid synthesis signaling pathways.
INTRODUCTION

Primary liver cancer is one of the fourth most common malignant tumors leading to death, hepatocellular carcinoma (HCC) is the most common form of primary liver cancer and is an important medical problem (1, 2). The development of HCC is closely related to the existence of chronic liver disease, the risk factors leading to HCC are known to mainly include hepatitis B virus (HBV), hepatitis C virus (HCV), alcohol, metabolic syndrome, diabetes, obesity, nonalcoholic fatty liver disease (NAFLD) and so on (2, 3). HCC treatment options vary and depend on tumor stages. For the early and intermediate stage, surgical resection image-guided ablation and chemoembolization treatments are mainly (2). However, most patients are diagnosed in advanced stages when HCC is discovered and are characterized by poor survival (4, 5). It’s because there is a lack of effective biomarkers to detect and treat HCC. Most recently, the FDA approved sorafenib, cabozantinib, lenvatinib and other drugs for the treatment of advanced HCC (6–8), but the overall survival of patients is still less than 1 year (9). Therefore, we urgently need to explore new oncogenes, especially those that can be used as targets for the treatment of HCC.

Platelet-activating factor acetyl hydrolase (PAF-AH), an acetylhydrolase, is known to induce the inactivation of the platelet-activating factor (PAF) through deacetylation (10). PAF-AH contains 3 subunits: PAFAH1B1, PAFAH1B2, and PAFAH1B3, with PAFAH1B2 and PAFAH1B3 exhibiting catalytic functions (11). Several studies have indicated the relationship between PAFAH1B3 and cancer progression. Blocking PAFAH1B3 and PAFAH1B2 have been shown to extensively affect lipid metabolism and upregulate the expression of lipids that inhibit breast cancer growth (12). Selective inhibition of PAFAH1B3 has been reported remarkably increased in gastric cancer cells, and high PAFAH1B3 expression was significantly correlated with proliferation, migration and immune infiltration (13). A previous study showed that PAFAH1B3 intervention might be useful for the treatment of HCC (14). However, the specific biological role of PAFAH1B3 in HCC and whether it is a therapeutic target remains unclear.

In our study, we used multiple cancer databases to analyze the PAFAH1B3 expression in various cancer, and further analyzed the prognostic value, co-expression genes, regulator networks of PAFAH1B3 in HCC. Importantly, further investigation in vitro revealed the correlation of PAFAH1B3 with proliferation, apoptosis, cell cycle, metastasis, and tumor-infiltrating immune cells. Finally, to further explore the potential relationship between PAFAH1B3 and tumor metabolic activity, we tested the expression of key targets involved in lipid and glucose metabolism. Our finding provides new insights into potential prognosis and therapeutic strategies for HCC.

Conclusion: Our findings suggested that PAFAH1B3 plays a critical role in progression of HCC. PAFAH1B3 as a prognosis marker and potential target for HCC has prospective clinical significance.

Keywords: PAFAH1B3, hepatocellular carcinoma, biomarker, prognosis, cancer databases

MATERIALS AND METHODS

ONCOMINE Dataset

The ONCOMINE online cancer database (https://www.oncomine.org/) was used to compare the transcription levels of PAFAH1B3 in multiple cancers (15). Several forms of HCC studies, including the Roessler Liver, Roessler Liver 2, Chen Liver, and Wurmbach Liver Study, were used in this analysis (16–18). This database allows the comparison of the relative transcript levels of PAFAH1B3 in cancer specimens and normal controls (15). The cutoff p-value was set as 0.01, and the fold change was set as 1.5.

GEPIA Dataset

GEPIA (http://geopia.cancer-pku.cn/) is a new web server for analyzing the gene expression profiling of 9736 cancer and 8587 normal samples produced by TCGA and Genotype-Tissue Expression (GTEx) projects (19). This database allows the analysis of differential gene expression, pathological stages, patient survival curves, and evaluation of similar genes and correlation in tumor and normal samples (19).

Human Protein Atlas Analysis

HPA (https://www.proteinatlas.org/) was used to analyze the protein expression of PAFAH1B3 in normal and HCC tissues (20).

HCCDB Dataset

HCCDB is an HCC online database for exploring the gene expression of 3917 clinical samples based on TCGA and GTEx. HCCDB provides functions such as differential gene expression analysis, survival analysis, and coexpression analysis (21).

UALCAN Dataset

The UALCAN (http://ualcan.path.uab.edu) interactive web portal was used to analyze the gene expression profiles of 31 cancer types based on TCGA and clinical samples (22). UALCAN allows the analysis of relative gene expression, clinicopathological features, and differential gene expression in individual cancer types (22).

LinkedOmics Dataset

LinkedOmics (23) is a multiomics database that integrates global proteomics data into TCGA tumor samples. It contains
multiomics and clinical data for 32 cancer types and 11,158 clinical samples based on the TCGA project. LinkedOmics provides 3 analysis modules, namely the LinkFinder, LinkCompare, and LinkInterpreter modules, to conduct a comprehensive analysis of the data. The cutoff FDR was set as 0.05, and the simulation was set to 1000. LinkedOmics is publicly available at (http://www.linkedomics.org/login.php).

**TIMER Analysis**

TIMER dataset (http://timer.comp-genomics.org/) was used to investigate the correlation between the expression of PAFAH1B3 and infiltration levels of immune cells (24).

**Cell Culture and Transfection**

Cell lines were acquired from the Cell Bank of the Type Culture Collection (Chinese Academy of Sciences, Shanghai, China). HepG2, MHCC-97H, Huh7, and LO2 were cultured in DMEM (Gibco, USA) supplemented with 10% fetal bovine serum (Gibco, USA) and antibiotics at 37°C and 5% CO2. HCC cell lines were transfected with siRNAs targeting PAFAH1B3 or control siRNA (Genechem, China) using Lipofectamine RNAiMAX (Invitrogen, USA). The efficiency of the knockdown was confirmed using qRT-PCR analysis. The siRNA used were as follows: PAFAH1B3 siRNA1: 5'- CGAC AGGUGAACCAGAGUGUATT-3'; PAFAH1B3 siRNA2: 5'-GGAGAGAAACCAGACGGUGAATT-3'.

**Growth Inhibition Assays**

For the in vitro studies, P11 (Cayman, USA), a selective inhibitor of PAFAH1B3, was dissolved in DMSO at a concentration of 50 mM, kept at -20°C as a stock solution. For the analysis of cell lines, HepG2, Huh7 and MHCC-97H cells were grown in drug-free medium for 3 days prior to experiences. The HCC cells were treated with various concentrations of P11 at -37°C for 48h. cells were treated DMSO instead of P11 served as control group. The experience was performed at least 3 times.

**Quantitative Real Time Polymerase Chain Reaction (qRT-PCR)**

Total RNA was isolated from HepG2, MHCC-97H, Huh7, and LO2 cell lines using the One Step TB Green® PrimeScript™ PLUS RT-PCR Kit (Takara, Beijing, China) according to the manufacturer’s protocol. All samples were run on a Roche LightCycler 480 machine. The cycles of target genes were normalized to those of the β-actin gene to obtain the ΔCT value. The expression of each target gene was presented as fold change, which was calculated through relative quantification using the 2-ΔΔCT method. The primers used were as follows: PAFAH1B3: Forward: 5'-ACATCCGGGCAAGATTGTG-3'; Reverse: 3'-GGGCTGTGTCCTACCAC-5'. PKM2: Forward: 5'-ATGTGAGCCCTATGTAAGA-3'; Reverse: 3'-TGGGTTGTGAATCAATTGTCCA-5'. GLUT1: Forward: 5'-GCGAGTAGGGTTCA-3'; Reverse: 3'-CTCTTCGGAAGGAGGTAGATCC-5'. PKF: Forward: 5'-GTACCTGGCGCTGTATCCG-3'; Reverse: 3'-CTCTCAGCGAATGGTGCTTC-5'. HK2: Forward: 5'-AGCAGAGCGACCATGCTACT-3'; Reverse: 3'-CCAGGATTCGCCGCAATTG-5'. FASN: Forward: 5'-AGCCTGTCTAGTTGTAGGC-3'; Reverse: 3'-TGGCTTCATAGGTAGTTCCA-5'. SREBP-1: Forward: 5'-TGCTTGCTGCCAGTGCTGTAG-3'; Reverse: 3'-AGGCGGTGGGACTGAGTTGGA-5'. β-actin: Forward: 5'-CATGTAGTTGCTATCCAGGC-3'; Reverse: 3'-TCCTTAAATGTCAAGCAGAT-5'.

**Cell Counting Kit-8 (CKK8) Assay**

The proliferation of HCC cells was assessed using the CCK-8 assay (Takara, China). Briefly, 2000 cells/well were incubated in triplicate in a 96-well plate, and 10 μl CCK-8 was added to each well after 48 h. After a 4h incubation at 37°C, the optical density (OD) value was measured at 450 nm absorbance.

**Western Blot**

For western blot analysis, the total cellular protein of HCC cells was obtained by RIPA lysis buffer. The protein concentration was determined using the bichinonic acid (BCA) assay (Fdbio Science, China). Equal amounts of protein sample were loaded to sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS–PAGE) and then transferred to the nitrocellulose filter membrane (GE Healthcare, USA). Next, membranes were incubated with the blocking buffer Tris-buffered saline/Tween 20 (TBST) in 5% bovine calf serum at room temperature for 1 hour and then incubated with primary antibody (CSTC64G5, CST4970L, ab150299, ab3259) overnight at 4°C and horseradish peroxidase (HRP)-conjugated secondary antibody. Signals of the protein were detected using an ImageQuant LAS 4000 auto-exposure system (GE Healthcare).

**Transwell Assay**

The transwell assay were using the 8.0μm transwell chamber (Corning, USA). DMEM medium without FBS was placed into the upper chambers to rehydrate the Matrigel (Corning, USA) for 2 hours at 37°C. Then remove the supernatants, one hundred thousand HCC cells containing DMEM medium without FBS were plated in the upper chamber. After incubation for 48 hours, the cells in the upper chambers were fixed with 4% paraformaldehyde for 15 minutes and stained with crystal violet for 20 minutes. The numbers of invading and migrating cells were counted in three randomly selected fields.

**Flow Cytometry Analysis**

We analyzed the apoptosis and cell cycle of HCC cell lines using Flow Cytometry. After indicated treatments, for the cell apoptosis analysis, HCC cells were collected separately, and incubated with Annexin-V (BioLegend, United States) in the dark at 4°C. After 10 min, the cells were analyzed using a FACSCantoTM II Flow Cytometer (BD, United States). For the cell cycle analysis, HCC cells were collected separately, and resuspend in 1 mL of ice-cold ethanol 70% overnight at 4°C, then incubated with RNaseA (Novoprotein, China) at 37°C for 30 min, then incubated with propidium iodide (PI) in the dark at 4°C for 30 min, then scanned in FACSCantoTM II Flow Cytometer.

**Statistical Analysis**

We performed differential gene expression and DNA copy number analyses between tumor and normal samples using the
t-test. The p-value and fold change were used to assess the statistical significance of the difference, with p < 0.01 and fold change >1.5 being considered significant. We also used t-test to conduct analysis of multiple clinicopathological characteristics of samples of patients with HCC from UALCAN, with p < 0.05 indicating significance. Kaplan-Meier curves were used to analyze the prognosis of patients with HCC with different median expression levels of PAFAH1B3. A log-rank test p < 0.05 indicated that the analysis was statistically significant. All experience data were analyzed using GraphPad 8.0.

FIGURE 1 | Expression of PAFAH1B3 in hepatocellular carcinoma (HCC). (A) The transcription level of PAFAH1B3 in TIMER databases. (B) The transcription level of PAFAH1B3 in ONCOMINE databases. (C) The protein expression of PAFAH1B3 in LiHC (HPA). (D) Boxplot showing the levels of PAFAH1B3 mRNA in the Roessler Liver. (E) Boxplot showing the levels of PAFAH1B3 mRNA in the Roessler Liver 2 datasets. (F) Boxplot showing the levels of PAFAH1B3 mRNA in the Chen Liver datasets. (G) Boxplot showing the levels of PAFAH1B3 mRNA in the Wurmbach Liver datasets. *p < 0.05; ***p < 0.001.
RESULT

Elevated Expression of PAFAH1B3 in a Variety of Malignant Tumors

We used the ONCOMINE, TIMER and HCCDB cancer database to analyze the mRNA expression of PAFAH1B3 in multiple cancer types. Our results show that PAFAH1B3 was highly expressed in a wide variety of malignant tumors compared with normal samples, including BLCA (P=3.20E-09), BRCA (P=3.20E-09), CHOL (P=2.04E-64), COAD (P=2.26E-09), ESCA (P=2.11E-07), HNSC (P=4.15E-13), KICH (P=5.04E-09), KIRC (P=0.041), KIRP (P=9.92E-06), LIHC (P=4.51E-20), LUAD (P=7.89E-35), LUSC (P=2.01E-31), PRAD (P=2.52E-13), READ (P=1.57E-07), STAD (P=1.69E-15), THCA (P=1.98E-22), UCEC (P=2.52E-13) (Figure 1A). The protein and mRNA expression of PAFAH1B3 was also highly expressed in HCC tissues (Figures 1B, C and Table 1). Several forms of HCC studies, including the Roessler Liver, Roessler Liver 2, Chen Liver, and Wurmbach Liver Study, also showed similar results (Figures 1D–G and Supplement Table 1). We observed that multiple clinicopathological analyses of PAFAH1B3 in the UALCAN database consistently showed the elevated transcription levels of PAFAH1B3 in HCC patients than healthy people in subgroup analyses based on age, gender, tumor grade, cancer stages, ethnicity and TP53 mutation (Table 2).

High Expression of PAFAH1B3 Is Associated With Poor Prognosis in HCC

We evaluated the prognostic value of PAFAH1B3 in a variety of malignant tumors using the GEPIA database. Patients were divided into two groups based on the median expression level of PAFAH1B3 in each cohort. We found that the increased expression of PAFAH1B3 was correlated with poor overall survival (OS) (P=0.0012) and disease-free survival (DFS)

### Table 1 | The expression of PAFAH1B3 in tumor tissues and the adjacent normal tissues, according to t-test in HCCDB.

| Dataset     | P-value | Type       | Num | Mean   | STD  | IQR    |
|-------------|---------|------------|-----|--------|------|--------|
| HCCDB1      | 2.28E-14| HCC        | 100 | 8.697  | 1.106| 1.585  |
|             |         | Adjacent   | 97  | 7.683  | 0.379| 0.4513 |
| HCCDB3      | 1.37E-27| HCC        | 268 | 0.9672 | 0.7824| 0.7668 |
|             |         | Adjacent   | 243 | 0.3788 | 0.1215| 0.153  |
|             |         | Cirrhotic  | 40  | 0.5489 | 0.1984| 0.3387 |
|             |         | Healthy    | 6   | 0.2823 | 0.056 | 0.0575 |
| HCCDB4      | 5.03E-66| HCC        | 240 | 8.834  | 1.126| 1.511  |
|             |         | Adjacent   | 193 | 7.092  | 0.461 | 0.5144 |
| HCCDB6      | 3.23E-48| HCC        | 225 | 5.121  | 0.7661| 1.168  |
|             |         | Adjacent   | 220 | 4.143  | 0.3332| 0.4088 |
| HCCDB7      | 0.0000237| HCC       | 80  | 12.09  | 0.6094| 0.7463 |
|             |         | Adjacent   | 82  | 11.68  | 0.5761| 0.824  |
| HCCDB11     | 0.05348 | HCC        | 88  | 11.72  | 1.617 | 1.973  |
|             |         | Adjacent   | 47  | 11.14  | 1.683 | 1.822  |
| HCCDB12     | 0.00000334| HCC    | 81  | 8.451  | 1.15  | 1.257  |
|             |         | Adjacent   | 80  | 7.73   | 0.6739| 0.7978 |
| HCCDB13     | 4.25E-26| HCC        | 228 | 5.658  | 0.9374| 1.326  |
|             |         | Adjacent   | 168 | 4.884  | 0.2996| 0.3545 |
| HCCDB15     | 1.76E-22| HCC        | 351 | 8.412  | 1.483 | 1.835  |
|             |         | Adjacent   | 49  | 6.967  | 0.6521| 1      |
| HCCDB16     | 0.001937| HCC        | 60  | 8.14   | 0.458 | 0.5118 |
|             |         | Adjacent   | 60  | 7.904  | 0.3497| 0.4085 |
| HCCDB17     | 0.002157| HCC        | 115 | 9.009  | 1.536 | 1.65   |
|             |         | Adjacent   | 52  | 8.496  | 0.5865| 0.68   |
| HCCDB18     | 1.23E-37| HCC        | 212 | 3.017  | 1.111 | 1.353  |
|             |         | Adjacent   | 177 | 1.737  | 0.569 | 0.62   |

### Table 2 | Expression of PAFAH1B3 in LIHC (Liver hepatocellular carcinoma) subgroups classified by age, sex, tumour grade, individual cancer stages, race, and TP53 mutational status (UALCAN).

| Clinicopathological characteristics | N       | P-value |
|------------------------------------|---------|---------|
| Age (Yrs)                          |         |         |
| 21-40                              | 27      | 1.75E-05|
| 41-60                              | 140     | 5.68E-07|
| 61-80                              | 181     | <1E-12  |
| 81-100                             | 10      | 5.14E-03|
| Gender                             |         |         |
| Male                               | 245     | 8.89E-10|
| Female                             | 117     | 1.62E-12|
| Grade                              |         |         |
| 1                                  | 54      | 3.63E-05|
| 2                                  | 173     | 1.62E-12|
| 3                                  | 118     | 8.39E-07|
| 4                                  | 12      | 1.50E-03|
| Stage                              |         |         |
| 1                                  | 168     | 1.62E-12|
| 2                                  | 84      | 4.50E-14|
| 3                                  | 82      | 2.04E-04|
| 4                                  | 6       | 3.31E-02|
| Race                               |         |         |
| Caucasian                          | 177     | <1E-12  |
| African-american                   | 17      | 8.76E-04|
| Asian                              | 157     | 5.11E-08|
| TP53 mutation                      |         |         |
| Yes                                | 105     | 3.32E-07|
| NO                                 | 255     | 1.62E-12|
(P=0.0047) in HCC (Figures 2A, B). Besides, high expression of PAFAH1B3 was also associated with overall survival in adrenocortical carcinoma (P=0.0035), acute myeloid leukemia (P=0.032), lung adenocarcinoma (P=0.008), mesothelioma (P=0.0022), sarcoma and skin cutaneous Melanoma (P=0.0038) (Supplement Figures 1A–F).

Coexpression Genes of PAFAH1B3 in Hepatocellular Carcinoma
We examined the genes coexpressed with PAFAH1B3 to explore common genetic risk factors in HCC. As shown in Figure 5A, 19,922 genes were shown to be significantly associated with PAFAH1B3. More specifically, several genes, such as PRR19, UBE2S, and SNRPA, showed a strong positive association with PAFAH1B3 (Figure 3A and Supplement Table 2). We found that the identified coexpressed genes were involved in cell cycle regulation (25), promotion of tumor growth, metastasis, and recurrence (26). Figure 3B shows the 50 significant genes positively and negatively correlated with PAFAH1B3 respectively. Then, co-expressed genes enrichment analysis was using Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) databases. The Go analysis results showed PAFAH1B3 co-expressed genes participate primarily in mitotic cell cycle phase transition, RNA catabolic processes, mRNA processing pathways (Supplement Figure 2A). The KEGG analysis results showed that spliceosome, ribosome, cell cycle and RNA transport were significantly enriched (Supplement Figure 2B). These results suggest that a widespread impact of PAFAH1B3 on the proliferation.

Regulators of PAFAH1B3 Networks in Hepatocellular Carcinoma
To further explore the targets of PAFAH1B3 in HCC, the generated kinase, miRNA, and transcription factor target networks of positively correlated gene sets were analyzed by GSEA. Our results showed that the ataxia telangiectasia mutated and Rad3-related (ATR), cyclin-dependent kinase 1 (CDK1), and polo-like kinase 1 (PLK1) kinases were the most significant target networks related to kinase-target regulation (Table 3). Moreover, these screened kinase genes were shown to be significantly related to HCC (27–29). We further noticed that the miRNA-target network was associated with (ATGTTAA) MIR-302C, (TAATAAT) MIR-126, (TGAATGT) MIR-181A, MIR-181B, MIR-181C, and MIR-181D (Table 3). The enrichment of transcription factors was shown to be related mainly to E2F, ELK1, and NRF1 (Table 3). We also observed that the identified transcription factors were also significantly related to HCC (30–32).

PAFAH1B3 mRNA Was Upregulated in Hepatocellular Carcinoma Cell Lines, PAFAH1B3 Silencing or Inhibitor P11 Impairing HepG2, Huh7 and MHCC-97H Proliferation and Metastasis
Firstly, we verified the mRNA expression of PAFAH1B3 in HCC cell lines. We found that the levels of mRNA expression of PAFAH1B3 were increased in HCC cell lines, especially in HepG2, compared with the LO2 liver cell line (p < 0.001) (Figure 4A). We verified that PAFAH1B3 was successfully silenced by siRNA in HepG2, Huh7 cells and MHCC-97H (p<0.0001) (Figure 4B). Next, we use the CCK8 assay to explore the effects of PAFAH1B3 silencing and pharmacological inhibition on proliferation of HCC cells. Our results showed that siRNA-induced silencing impaired the proliferation of HepG2, Huh7 and MHCC-97H cells (p<0.0001) (Figure 4C). P11 could also impaired the proliferation of HepG2, Huh7 and MHCC-97H cells in a concentration dependent manner (Figure 4D). Besides, transwell assay results showed that PAFAH1B3 silencing also
FIGURE 3 | Coexpression of PAFAH1B3 in hepatocellular carcinoma (HCC) (LinkedOmics). (A) Total genes highly correlated with PAFAH1B3. (B) Heatmaps showing the 50 significant genes positively and negatively correlated with PAFAH1B3 in LIHC. Red and blue indicate positively and negatively correlated genes, respectively.
significantly impaired the invasion and migratory ability of HCC cells (Figures 4E, F). These results suggested that high expression of PAFAH1B3 was associated with the proliferation and metastasis of HCC cell lines.

PAFAH1B3 Silencing and P11 Induce Cell Cycle Arrest and Apoptosis

Then we further explore the effects of PAFAH1B3 on distribution of the cell cycle and apoptosis in HCC cells by flow cytometric analysis. PAFAH1B3 was silenced by siRNA or pharmacological inhibited by P11 with 20 μM dose for 48 hours. As shown in Figures 5A, B, P11 was significantly induced apoptosis in HepG2, huh7 and MHCC-97H cells, PAFAH1B3 siRNA was only induced apoptosis in HepG2 and MHCC-97H, but not in Huh7. P11, a selective inhibitor of PAFAH1B3, also could target PAFAH1B2. Therefore, we used ONCOMINE online cancer database to analyze the mRNA expression of PAFAH1B1 and PAFAH1B2 in HCC found that the mRNA expression of PAFAH1B1 and PAFAH1B2 was no significant changes in HCC (Supplement Figure 3). So, we did not continue to study the role of PAFAH1B2 in HCC, but our results showed that both PAFAH1B2 and PAFAH1B3 inhibition could have better effector than PAFAH1B3 siRNA in Huh7 cells. Next, we found that PAFAH1B3 silencing or P11 increased the percentage of HepG2 in sub-G1 phase (Figures 5C, D). PAFAH1B3 silencing or P11 induced G0/G1 cell cycle arrest in Huh7 and MHCC-97H (Figures 5E–H). These results implied that targeting PAFAH1B3 exerts potent antitumor effects in HCC cell lines by inducing cell cycle arrest and apoptosis.

PAFAH1B3 Silencing Downregulated the Expression of Glycolysis and Lipid Synthesis Signaling Pathways

We next investigated whether the metabolic genes of HCC were regulated by PAFAH1B3 silencing in HepG2, Huh7 and MHCC-97H cells. In the present study, qRT-PCR showed glycolysis- and lipid synthesis-related genes, including PKM2, HK2, GLUT1, PFK, FASN and SREBP-1, were significantly downregulated by the silencing of PAFAH1B3 in HepG2, Huh7, and MHCC-97H cells (Figures 6A–C). Finally, we verified the impact of PAFAH1B3 on lipid synthesis and glycolysis signaling pathways by western blot. The results show that PAFAH1B3 Silencing in HepG2, Huh7 and MHCC-97H led to the obviously downregulated levels of Glut1. And the levels of HK2 and SREBP1 were slightly downregulated (Figure 6D). Taken together, the PAFAH1B3 participated in maintaining metabolic homeostasis in HCC cells.

DISCUSSION

HCC is one of the most common cancers in the world, there is currently no effective treatment for HCC. Therefore, new therapeutic targets to treat HCC are urgently needed. In recent years, PAFAH1B3, as a pan-cancer target, is found to be significantly upregulated in a variety of malignant tumors. Recent studies showed PAFAH1B3 as a key metabolic driver was correlated with poor prognosis, and PAFAH1B3 knockdown or pharmacological inhibition impaired cancer cell survival through enhancing tumor-suppressing signaling lipids (33, 34). Similarly, PAFAH1B3 was also highly expressed in gastric cancer cells and osteosarcoma cells, and PAFAH1B3 knockdown was impaired cancer cell proliferation (13, 35). However, the biological role of PAFAH1B3 in HCC remains unclear.

Firstly, we demonstrated that PAFAH1B3 was highly expressed in a wide variety of malignant tumors compared with normal samples. And, high expression of PAFAH1B3 was also associated with overall survival. Besides, high expression of PAFAH1B3 predicted the poor prognosis of patients with HCC and showed that it was related to tumor stage and survival rate. Our results showed that PAFAH1B3 can be used as a pan-cancer marker for tumor prognosis.

To further study the role of PAFAH1B3 in HCC, we used the LinkedOmics function module to analyze PAFAH1B3
co-expressed genes to further explore the biological significance of PAFAH1B3 in HCC. We accordingly found that related functional networks were involved in cell cycle, cell metabolism, spliceosome, and RNA transport. Co-expression genes have been shown to be involved in protein degradation and signal transduction, promoting proliferation of multiple tumors, such as melanoma (36) and gastric cancer (37). We assessed the regulators of PAFAH1B3 in HCC by analyzing the
enrichment of kinases, miRNAs, and transcription factors (TF) of PAFAH1B3 positively related genes and found that PAFAH1B3 was primarily related to the CDK1 and PLK1 kinases in HCC (Supplement Table 1). Overexpression of CDK1 and PLK1 has been reported to cause malignant transformation of hepatocytes, defining a subgroup of high-risk patients (29, 38). The E2F family has been implicated as the main transcription factor in the abnormal regulation of

FIGURE 5 | The effects of PAFAH1B3 on HCC cell apoptosis and cell cycle. (A, B) The flow cytometry analysis revealed the effects of PAFAH1B3 silencing or inhibitor P11 on cell apoptosis. (C–H) Cell cycle analysis in HepG2, Huh7 and MHCC-97H cells. *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001. NS, no significance.
PAFAH1B3, with the E2F signal being shown to interact with the transcription program to promote the development of HCC (39).

Then, we verified the mRNA expression of PAFAH1B3 in MHCC-97H, Huh7, HepG2, and LO2 cells. We found that the mRNA expression of PAFAH1B3 in HCC cell lines was higher than that in LO2. We anticipated that these results would be useful for improving current treatment regimens and outcomes of HCC. To further explore whether PAFAH1B3 can be used as a target for the treatment of HCC, we tested the proliferation of HepG2, Huh7 and MHCC-97H cells after silencing or pharmacologic inhibitor of PAFAH1B3. On the one hand, our results suggested that the proliferation of HepG2, Huh7 and MHCC-97H was significantly suppressed after silencing or pharmacologic inhibitor of PAFAH1B3. On the other hand, PAFAH1B3 silencing significantly impaired HCC cells migration and invasion potential, suggesting that PAFAH1B3 plays an important role in maintaining the aggressive properties of HCC cells. In line with our findings, it has been reported that PAFAH1B3 knockdown suppressed cells proliferation and impaired cells metastasis in breast cancer and gastric cancer (13, 33). A recent study showed that palmitoylation of PAFAH1b3 was required to promote cell migration and PAFAH1b3 knockdown abrogated the ability of VEGF (and insulin) to stimulate angiogenesis (40). Next, we found that targeting PAFAH1B3 could significantly induce cell cycle arrest in HCC cells and induce apoptosis in HCC cells, PAF-AH contains 3 subunits: PAFAH1B1, PAFAH1B2, and PAFAH1B3. However, we found that the mRNA expression of PAFAH1B1 and PAFAH1B2 was no significant changes in HCC. In line with our findings, PAFAH1B2 was no significantly upregulated in human breast tumors, but targeting PAFAH1B2 could also significantly impaired proliferation, survival, migration, and invasiveness in breast cancer cells (34). So, the functions of PAFAH1B2 and PAFAH1B3 need further exploration.

In addition, PAFAH1B3 silencing significantly downregulated Glycolysis and lipid metabolism signaling pathway. PAFAH1B3, a newly discovered metabolic enzyme, was correlated with infiltration of immune cells in HCC (Supplement Figure 4). Metabolomics analysis revealed that PAFAH1B3 promotes tumor invasion by regulating the precancer signaling lipid metabolism network; thus, targeting PAFAH1B3 was shown to upregulate the pathogenicity of tumor suppressor lipids to attenuate cancer (12, 34). Several studies have shown that targeting metabolic enzymes could effectively inhibit tumor growth and promote infiltration of T-cells, thus rendering tumors more responsive to immune checkpoint therapy (41–43). Our early study showed that adoptive transfer of the AFP TCR-T could eradicate HepG2 tumors in NSG mice (44). Whether targeting PAFAH1B3 can affect the anti-tumor immune response remains to be verified.

CONCLUSION

In summary, our study demonstrated that PAFAH1B3 has important prognosis value as a biomarker for HCC. By targeting PAFAH1B3, the proliferation and metastasis of HepG2, Huh7 and MHCC-97H cells was inhibited. Mechanistically, we found PAFAH1B3 was involved in regulation of cell cycle, apoptosis, and metabolism in HCC cell.
lines. Altogether, PAFAH1B3 may be used as a prognostic biomarker and potential therapy target for HCC.

DATA AVAILABILITY STATEMENT

The datasets presented in this study can be found in online repositories. The names of the repository/repositories and accession number(s) can be found in the article/Supplementary Material.

AUTHOR CONTRIBUTIONS

XZ, WZ, and HL conceived and supervised the study. WX, XL, and JL designed experiments. WX, XL, QC, and XH performed experiments. XL, JL, QC, and KH analyzed data. WX wrote the manuscript. XZ, WZ, and HL made manuscript revisions. All authors contributed to the article and approved the submitted version.

FUNDING

This study was supported by National Natural Science Foundation of China (grant number 81802449; 81871664).

REFERENCES

1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin (2018) 68(6):394–424. doi: 10.3322/caac.21492

2. Forner A, Reig M, Bruix J. Hepatocellular Carcinoma. Lancet (2018) 391(10127):1301–14. doi: 10.1016/s0140-6736(18)30010-2

3. McGlynn KA, Petrick JL, Serag HB. Epidemiology of Hepatocellular Carcinoma. Hepatology (2021) 73 Suppl 1:4–13. doi: 10.1002/hep.31288

4. Xu J, Zang Y, Cao S, Lei D, Pan X. Aberrant Expression of PAFAH1B3 in Hepatocellular Carcinoma. Front Oncol (2021) 11:700700. doi: 10.3389/fonc.2021.700700

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fonc.2021.700700/full

Supplementary Figure 1 | Prognostic Value of PAFAH1B3 in various cancer types. Overall survival of PAFAH1B3 was analyzed using GEPIA database in (A) adenocortical carcinoma, (B) acute myeloid leukemia, (C) lung adenocarcinoma, (D) mesothelioma, (E) sarcoma, (F) skin cutaneous Melanoma.

Supplementary Figure 2 | Gene ontology annotations and KEGG pathways enriched with PAFAH1B3 Co-expressed genes in hepatocellular carcinoma (LinkedOmics). GSEA was used to analyze the significantly enriched GO_BP, and KEGG pathways of PAFAH1B3 Co-expressed genes in LHC. (A) Gene ontology biological processes, analyzed by GSEA. (B) KEGG pathway, analyzed by GSEA. The LeadingEdgeNum and the false discovery rate (FDR) are shown in blue and orange columns, respectively.

Supplementary Figure 3 | Expression of PAFAH1B1 and PAFAH1B2 in HCC.

Supplementary Figure 4 | Correlation between PAFAH1B3 expression and immune cell infiltration levels in HCC tissues analyzed via TIMER.

Supplementary Table 1 | The statistics of PAFAH1B3 expression in LIHC based on ONCOMINE.

Supplementary Table 2 | The top 50 co-expressed genes of PAFAH1B3 (LinkedOmics).
21. Jian Q, Wang S, Zhang G, Wang D, Luo G, Tang J, et al. HCCDB: A Database of Hepatocellular Carcinoma Expression Atlas. Genomics Proteomics Bioinf (2018) 16(4):269–75. doi: 10.1016/j.gpb.2018.07.002
22. Chandrashekar DS, Bashel B, Balasubramanya SAH, Creighton CJ, Ponce-Rodriguez I, Chakravarti B, et al. UALCAN: A Portal for Facilitating Tumor Subgroup Gene Expression and Survival Analyses. Neoplasia (2017) 19(8):649–58. doi: 10.1016/j.neo.2017.05.002
23. Vasaiak S, Straub P, Wang J, Zhang B. LinkedOmic: Analyzing Multi-Omics Data Within and Across 32 Cancer Types. Cancer Res (2018) 78(13):956–963. doi: 10.1158/1535-7163.AM2018-2295
24. Li T, Fan J, Wang B, Traugh N, Chen Q, Liu JS, et al. TIMER: A Web Server for Comprehensive Analysis of Tumor-Infiltrating Immune Cells. Cancer Res (2017) 77(21):e108–e10. doi: 10.1158/0008-5472.CAN-17-0307
25. Kent LN, Leone G. The Broken Cycle: EZF Dysfunction in Cancer. Nat Rev Cancer (2019) 19(6):326–38. doi: 10.1038/s41568-019-0143-7
26. Bondarieva A, Raveendran K, Telychko V, Rao H, Ravindranathan R, Zoromzokou C, et al. Proline-Rich Protein PRR19 Functions With Cyclin-Like CNDT1 to Promote Meiotic Crossing Over in Mice. Nat Commun (2020) 11(1):3101. doi: 10.1038/s41467-020-16885-3
27. Diab A, Foca A, Fusil F, Lahalali J, Jalaguer P, Amirache F, et al. Polo-Like Kinase 1 Is a Proviral Host Factor for Hepatitis B Virus Replication. Hepatology (2017) 66(6):1750–65. doi: 10.1002/hep.29236
28. Wang B, Fu J, Yu T, Xu A, Qin W, Yang Z, et al. Contradictory Effects of Mitochondria- and Non-Mitochondria-Targeted Antioxidants on Hepatocarcinogenesis by Altering DNA Repair in Mice. Hepatology (2018) 67(2):623–35. doi: 10.1002/hep.29518
29. Li C, Wu L, Liu P, Li K, Zhang Z, He Y, et al. The C/D Box Small Nucleolar RNA SNORD52 Regulated by Upf1 Facilitates Hepatocarcinogenesis by Stabilizing CDK1. Theranostics (2020) 10(20):9348–63. doi: 10.7150/thno.74677
30. Chen J, Wang M, Xiang Y, Xu R, Ren Y, Liu X, et al. Nrf1 Is Endowed With a Dominant Tumor-Represing Effect Onto the Wnt/b-Catenin-Dependent and Wnt/b-Catenin-Independent Signaling Networks in the Human Liver Cancer. Oxid Med Cell Longev (2020) 2020:138539. doi: 10.1155/2020/5138539
31. Ma G, Huang S, Xu L, Tian L, Yang Y, Wang J. Transcription Co-Activator P300 Activates Elk1-aPKC-t Signaling Mediated Epithelial-to-Mesenchymal Transition and Malignancy in Hepatocellular Carcinoma. Oncogenes (2020) 9(3):32. doi: 10.1038/s41389-020-0122-5
32. Kent LN, Bae S, Tsai SY, Tang X, Srivastava A, Koivistola C, et al. Dosage-Dependent Copy Number Gains in EZF1 and EZF3 Drive Hepatocellular Carcinoma. J Clin Invest (2017) 127(3):830–42. doi: 10.1172/jci87585
33. Chang JW, Zuhl AM, Speers AE, Niessen S, Brown SJ, Mulvihill MM, et al. Selective Inhibitor of Platelet-Activating Factor Acetylhydrolases 1b2 and 1b3 That Impairs Cancer Cell Survival. ACS Chem Biol (2015) 10(4):925–32. doi: 10.1021/cb500893q
34. Mulvihill MM, Benjamin DI, Ji X, Le Scolan E, Louise SM, Shieh A, et al. Metabolic Profiling Reveals PAFAH1B3 as a Critical Driver of Breast Cancer Pathogenicity. Chem Biol (2014) 21(7):831–40. doi: 10.1016/j.chembiol.2014.05.008
35. Fan J, Yang Y, Qian JK, Zhang X, Ji JQ, Zhang L, et al. Aberrant Expression of PAFAH1B3 Affects Proliferation and Apoptosis in Osteosarcoma. Front Oncol (2021) 11:640. doi: 10.3389/fonc.2021.640874
36. Wang P, Li Y, Ma Y, Zhang X, Li Z, Yu W, et al. Comprehensive Investigation Into the Role of Ubiquitin-Conjugating Enzyme E2S in Melanoma Development. J Invest Dermatol (2021) 141(2):374–84. doi: 10.1016/j.jid.2020.05.113
37. Dou N, Yang D, Yu S, Wu B, Gao Y, Li Y. SNRPA Enhances Tumour Cell Growth in Gastric Cancer Through Modulating NGF Expression. Cell Proplf (2018) 51(5):e12484. doi: 10.1111/cpr.12484
38. Bayo J, Fiore EJ, Dominguez LM, Real A, Malvicini M, Rizzo M, et al. A Comprehensive Study of Epigenetic Alterations in Hepatocellular Carcinoma Identifies Potential Therapeutic Targets. J Hepatol (2019) 71(1):78–90. doi: 10.1016/j.jhep.2019.03.007
39. Kent LN, Rakijas JR, Pandit SK, Westendorp B, Chen HZ, Huntington JT, et al. EZF8 Mediates Tumor Suppression in Postnatal Liver Development. J Clin Invest (2016) 126(8):2955–69. doi: 10.1172/JCI85506
40. Wei X, Song H, SemenovKich CF. Insulin-Regulated Protein Palmitoylation Impacts Endothelial Cell Function. Arterioscler Thromb Vasc Biol (2014) 34(2):346–54. doi: 10.1161/1atvba.113.302848
41. Yang W, Bai Y, Xiong Y, Zhang J, Chen S, Zheng X, et al. Potentiating the Antitumour Response of CD8+ T Cells by Modulating Cholesterol Metabolism. Nature (2016) 531(7596):651–5. doi: 10.1038/nature17412
42. Jiang Y, Sun A, Zhao Y, Ying W, Sun H, Yang X, et al. Proteomics Identifies New Therapeutic Targets of Early-Stage Hepatocellular Carcinoma. Nature (2019) 567(7747):257–61. doi: 10.1038/s41586-019-0987-8
43. Liu X, Yao X, Hu M, Chang H, Jiao M, Cheng J, et al. Inhibition of PCSK9 Potentiates Immune Checkpoint Therapy for Cancer. Nature (2020) 588(7839):693–8. doi: 10.1038/s41586-020-2911-7
44. Zhu W, Peng Y, Wang L, Hong Y, Jiang X, Li Q, et al. Identification of α-Fetoprotein-Specific T-Cell Receptors for Hepatocellular Carcinoma Immunotherapy. Hepatology (2018) 68(2):574–89. doi: 10.1002/hep.29844

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2021 Xu, Lu, Liu, Chen, Huang, Huang, Liu, Zhu and Zhang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.